Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Other financing activities (2016)

Intellia Therapeutics (NTLA) has disclosed Other financing activities for 2 consecutive years, with $1.7 million as the latest value for Q3 2016.

  • On a quarterly basis, Other financing activities changed N/A to $1.7 million in Q3 2016 year-over-year; TTM through Dec 2016 was $2.8 million, a N/A change, with the full-year FY2018 number at $424000.0, changed N/A from a year prior.
  • Other financing activities was $1.7 million for Q3 2016 at Intellia Therapeutics, up from $215000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $1.7 million in Q3 2016 to a low of $207000.0 in Q4 2015.